An FDA labeling update expands where SKINVIVE may be discussed.
A June 2026 FDA supplement describes SKINVIVE by JUVEDERM for cheek smoothness and for reducing neck lines in adults over 21. Approval language does not replace an individual medical evaluation.
Reviewed for the Dagan Edit
Share quietly
Renaissance-style injectables study representing skin-quality and hyaluronic-acid treatment planning; not an actual patient result
The report, in context
What this development means—and what it does not.
A June 2026 FDA supplement describes SKINVIVE by JUVEDERM for cheek smoothness and for reducing neck lines in adults over 21. Approval language does not replace an individual medical evaluation.
Inclusion is not an endorsement; treatment suitability, product safety and postoperative care require individualized guidance from a qualified clinician.
